Dermatology

We support the scientific advancement

of your Skin and Hair Therapeutic products

Dermatology & Immunodermatology Solutions

Translational Models & Assays to Advance Your Pipeline From Discovery to Clinical Testing

Are you looking for validated assays and innovative solutions to demonstrate the efficacy of your dermatological formulations or evaluate new drug candidates?

Do you need to characterize active ingredients, screen for target engagement in early discovery, or gain deeper insights into your drug’s mechanism of action?

At QIMA Life Sciences, we provide scientifically grounded, clinically relevant solutions to support the development of treatments for a wide range of skin disorders, including psoriasis, atopic dermatitis, hidradenitis suppurativa, chronic urticaria, pemphigoid diseases, and many others.

• From Biomarkers to Mechanism of Action

Our platforms are designed to assess the modulation of key biological processes, such as:

    • Cytokine inhibition (e.g., IL-4, IL-13, IL-17, IL-23, TSLP)
    • JAK/STAT pathway modulation
    • Type I interferon signaling
    • Barrier restoration and immune cell activation

We help characterize the effects of your compounds through gene expression profiling and analysis of molecular and cellular responses. By precisely selecting and validating quantitative biomarkers and readouts, we provide also mechanistic insights and enhance translational relevance.

Regardless of the drug class—whether small molecules, biologics, biosimilars, peptides, or mono-/bispecific antibodies—our in vitro, ex vivo, and functional assays support rapid, reproducible evaluation of immunomodulatory activity and therapeutic potential.

• Integrated Preclinical and Clinical Research Capabilities

QIMA Life Sciences offers a seamless continuum of research services, from early-stage discovery to clinical evaluation:

PRECLINICAL SERVICES:

  • In vitro & ex vivo screening of active compounds
  • In vivo efficacy models
  • Mechanism of action studies
  • Safety testing and regulatory-oriented protocols
  • Advanced co-culture systems for complex disease modeling

CLINICAL SERVICES:

  • Our dedicated clinical unit sites enable early-phase studies, including Phase I and Phase IIa clinical trials
  • We also offer advanced clinical skin image analysis, powered by proprietary AI-based algorithms for automated and quantitative analysis of dermatological parameters
  • Our solutions also include standardized image capture systems, enabling consistent and objective data collection across study sites

• Tailored Study Design & Scientific Guidance

Our expert team works with you to:

  • Select the most relevant models based on disease context and target biology
  • Customize study design to match your regulatory and scientific goals
  • Provide regular updates, transparent reporting, and expert interpretation

A Trusted Partner in Immunodermatology Innovation

With over 20 years of experience in skin biology, immunopharmacology, and biomarker-based development, QIMA Life Sciences is your partner to de-risk and accelerate the journey from early discovery to clinical translation.

Let us help you bring your next dermatology breakthrough to life — with science at the core.

Unique Access to Human Skin, Hair & Blood Samples from Healthy Donors and Patients

We provide access to a diverse biobank of healthy and pathological skin and hair samples, collected through our network of dermatologists and surgeons. These samples are used to:

  • Isolate primary cells from diseased tissue
  • Identify targets
  • Identify and validate disease-specific biomarkers
  • Maintain functional ex vivo organ cultures for compound testing

This ensures high physiological relevance for early efficacy and safety evaluation and offers the highest degree of prediction.

Preclinical & Clinical Research in Dermatology

We can support you with:

We offer state-of-the-art techniques, e.g. (single cell) RNAseq, laser capture microdissection, applied to healthy and diseased tissue samples and pre-clinical models to identify novel targets in skin and hair disorders that can be modulated by pharmaceutical, cosmeceutical or nutraceutical compounds.

We offer state-of-the-art techniques, e.g. in situ hybridization, multiplex immunostainings, applied to healthy and diseased tissue samples and pre-clinical models to examine the source, expression and localization of your target of interest in healthy and diseased skin and hair samples.

We offer pre-clinical models, and state-of-the-art techniques, including gene silencing ex vivo, to study if modulation of your target of interest provides an efficient therapeutic benefit on skin and hair pathology within an acceptable safety window.

We offer pre-clinical models to identify the underlying molecular mechanisms in skin and hair samples addressed by your target.

We perform targeted screening of bioactive compounds using a variety of advanced in vitro models relevant to skin and hair biology. Our platforms allow early identification of compounds with potential efficacy based on pharmacological activity, cellular response, and biomarker modulation. Screening strategies can be tailored to specific endpoints such as anti-inflammatory effects, antioxidant capacity, sebum regulation, or hair growth stimulation.

We use state-of-the-art techniques and pre-clinical models, including organ culture of diseased skin samples to identify and establish biomarkers as early indicators for skin and hair disease progression.

We use pre-clinical models, including organ culture of diseased skin samples, to predict treatment responses induced by your target of interest, in skin and hair pathologies.

We offer pre-clinical models to examine the efficacy and safety of your compound on targets of interest in comparison to well known agents.

We offer pre-clinical models to test if the modulation of your target of interest efficiently affects skin and hair biology, ameliorates experimentally-induced pathological conditions or the phenotype of diseased samples.

We offer pre-clinical models to investigate the localization and distribution of your compound/drug/nutraceutical in skin and hair samples to support the selection of best mode or vehicle for administration.

We are happy to help you in customizing assays to optimally meet your research needs, and to join forces to establish clinically-meaningful models.
We are constantly working on the establishment of new assays,

We offer a panel of in vitro safety assays to assess the preliminary toxicological and pharmacological profile of compounds before progressing to advanced studies. These include cytotoxicity, phototoxicity, skin irritation, and sensitization assays using reconstructed human tissue models. Non-GLP PK/PD approaches are also available to investigate compound penetration, metabolism, and local bioavailability in skin models, helping to predict in vivo behavior and guide formulation optimization.

We provide comprehensive analytical support to ensure product compliance with regulatory standards through leachables, extractables, impurities, and nitrosamine testing. Our state-of-the-art instrumentation and validated methods allow the detection and quantification of trace-level contaminants. These studies are essential for risk assessment, regulatory submissions, and ensuring product safety throughout its lifecycle.

Latest Insights

SCIENTIFIC NEWS & AGENDA
123456789
PUBLICATIONS & ARTICLES

Do you have a project requiring in vitro dermatological expertise? Let’s talk about it!

CONTACT US